德国生物科技公司BioNTech(BNTX.US)11月6日盘中股价大跌5.19%,报收105.32美元,成为市场关注焦点。据悉,这家新冠疫苗研发商在去年实现了巨额营收和利润,但最新季度业绩可能令投资者失望,进而引发股价剧烈波动。
BioNTech联手辉瑞研发的Comirnaty新冠疫苗是两家公司共同的重磅产品。随着新冠疫情形势趋缓,全球疫苗需求逐步降温,这种外部环境变化可能直接导致BioNTech的疫苗收入大幅减少。
此外,BioNTech也在布局多个前景广阔的抗癌药物和疫苗管线,持续高额研发投入或许也为公司业绩带来一定压力。从长远来看,公司是否能及时实现多元化转型,将决定其未来发展前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.